Your browser doesn't support javascript.
loading
Multimodality Treatment of Desmoplastic Small Round Cell Tumor: Chemotherapy and Complete Cytoreductive Surgery Improve Patient Survival.
Subbiah, Vivek; Lamhamedi-Cherradi, Salah-Eddine; Cuglievan, Branko; Menegaz, Brian A; Camacho, Pamela; Huh, Winston; Ramamoorthy, Vandhana; Anderson, Pete M; Pollock, Raphael E; Lev, Dina C; Qiao, Wei; McAleer, Mary Frances; Benjamin, Robert S; Patel, Shreyaskumar; Herzog, Cynthia E; Daw, Najat C; Feig, Barry W; Lazar, Alexander J; Hayes-Jordan, Andrea; Ludwig, Joseph A.
Afiliación
  • Subbiah V; Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas. jaludwig@mdanderson.org vsubbiah@mdanderson.org.
  • Lamhamedi-Cherradi SE; Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Cuglievan B; Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Menegaz BA; Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Camacho P; Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Huh W; Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Ramamoorthy V; Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Anderson PM; Department of Pediatric Hematology/Oncology/BMT, Cleveland Clinic Foundation, Cleveland, Ohio.
  • Pollock RE; Division of Surgical Oncology, Ohio State University, Columbus, Ohio.
  • Lev DC; Division of Surgical Oncology, Ohio State University, Columbus, Ohio.
  • Qiao W; Division of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • McAleer MF; Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Benjamin RS; Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Patel S; Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Herzog CE; Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Daw NC; Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Feig BW; Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Lazar AJ; Division of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Hayes-Jordan A; Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Ludwig JA; Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas. jaludwig@mdanderson.org vsubbiah@mdanderson.org.
Clin Cancer Res ; 24(19): 4865-4873, 2018 10 01.
Article en En | MEDLINE | ID: mdl-29871905
ABSTRACT

Purpose:

Desmoplastic small round cell tumor (DSRCT), which harbors EWSR1-WT1 t(11;22)(p13q12) chromosomal translocation, is an aggressive malignancy that typically presents as intra-abdominal sarcomatosis in young males. Given its rarity, optimal treatment has not been defined.Experimental

Design:

We conducted a retrospective study of 187 patients with DSRCT treated at MD Anderson Cancer Center over 2 decades. Univariate and multivariate regression analyses were performed. We determined whether chemotherapy, complete cytoreductive surgery (CCS), hyperthermic intraperitoneal cisplatin (HIPEC), and/or whole abdominal radiation (WART) improve overall survival (OS) in patients with DSRCT. Critically, because our institutional practice limits HIPEC and WART to patients with less extensive, potentially resectable disease that had benefited from neoadjuvant chemotherapy, a time-variant analysis was performed to evaluate those adjunct treatment modalities.

Results:

The pre-2003 5-year OS rate of 5% has substantially improved to 25% with the advent of newer chemotherapies and better surgical and radiotherapy techniques (HR, 0.47; 95% CI, 0.29-0.75). Chemotherapy response (log rank P = 0.004) and CCS (log rank P < 0.0001) were associated with improved survival. Although WART and HIPEC lacked statistical significance, our study was not powered to detect their potential impact upon OS.

Conclusions:

Improved 3- and 5-year OS were observed following multidisciplinary treatment that includes Ewing sarcoma (ES)-based chemotherapy and complete tumor cytoreductive surgery, but few if any patients are cured. Prospective randomized studies will be required to prove whether HIPEC or WART are important. In the meantime, chemotherapy and CCS remain the cornerstone of treatment and provide a solid foundation to evaluate new biologically targeted therapies. Clin Cancer Res; 24(19); 4865-73. ©2018 AACR.
Asunto(s)

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Sarcoma de Ewing / Tumor Desmoplásico de Células Pequeñas Redondas / Procedimientos Quirúrgicos de Citorreducción Tipo de estudio: Clinical_trials / Observational_studies / Risk_factors_studies Límite: Adult / Female / Humans / Male Idioma: En Revista: Clin Cancer Res Asunto de la revista: NEOPLASIAS Año: 2018 Tipo del documento: Article

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Sarcoma de Ewing / Tumor Desmoplásico de Células Pequeñas Redondas / Procedimientos Quirúrgicos de Citorreducción Tipo de estudio: Clinical_trials / Observational_studies / Risk_factors_studies Límite: Adult / Female / Humans / Male Idioma: En Revista: Clin Cancer Res Asunto de la revista: NEOPLASIAS Año: 2018 Tipo del documento: Article